Recommendation on Cross Border Genetic Testing of Rare Diseases in the European Union
On 13th November 2015, the Commission Expert Group on Rare Diseases adopted Recommendations on Cross-Border Genetic Testing of Rare Diseases in the European Union. The Recommendations are addressed to the Member States and the European Commission and focus specifically on the issues of cross-border testing. There is significant variation between EU Member States in terms of the number of genetic tests available in-country for RD – some countries test for fewer than 20 genes, whilst others test for over 2000. Even with the increasing use of Next Generation Sequencing, there will remain a need for countries to conduct some genetic tests for RD on a cross-border basis. Building upon previous expert discussions and workshops, research was conducted under the EUCERD Joint Action by partner Helena Kääriäinen, which explored the volume of cross-border genetic testing for RD and highlighted some of the key challenges involved in the process. Following an expert workshop in December 2014, draft Recommendations were elaborated, with the aim of generating meaningful impact in this area. They emphasise the need to:
• facilitate access to cross-border genetic testing, where appropriate
• collaborate across borders to assess the added-value of genetic testing
• share expertise and collaborate at the European level
• ensure reliable information on laboratories providing genetic testing for RD
Access the report
An article published in JIMD Report reports on the inborn errors of metabolism (IEM) detected by the national newborn screening in the United Arab Emirates between 2011 and 2014. The study reports 114 patients diagnosed during this period giving an incidence of 1 in 1,787 citizens. According to the authors Emirati citizens have diverse geo-ethnicities, which include ancestors from the Arabian Peninsula, Persia, Baluchistan, and East Africa whose tribal culture favors consanguineous marriages which has resulted in the relatively high prevalence of IEM. The authors report that biotinidase deficiency, phenylketonuria, 3-methylcrotonyl glycinuria, medium-chain acyl-CoA dehydrogenase deficiency, argininosuccinic aciduria, glutaric aciduria type 1, glutaric aciduria type 2, and methylmalonyl-CoA mutase deficiency account for 80% of the diagnosed disorders with the identification of many clinically significant which could be included in spremarital screening. The authors believe that high prevalence of IEM in can be combatted by newborn and premarital screening. 
A description of the Undiagnosed Disease Network (UDN)- an extension of the Undiagnosed Diseases Program (UDP) set up by the National Institutes of Health (NIH), is published in JAMA. UDP evaluates patients and families for whom medicine has failed to provide a diagnosis. Of the 6000 annual calls to the Genetic and Rare Diseases Information Center, 6% are from persons without a diagnosis, and 15% of patients with rare diseases spend more than 5 years searching for a diagnosis. Participants in the UDP are chosen based on objective signs and symptoms, the unique nature of the problem, and an estimate by the UDP of its ability to make a diagnosis. According to the article comprehensive clinical assessment represents only the beginning and the UDN acts an extension which allows the analysis and sharing of data which enhances the working of UDP. The UDN has an opening of an online patient application portal, called the UDN Gateway, through which patients and their physicians can register and apply. 
The Australian Government is currently conducting the first review of the entire Medicare Benefits Scheme (MBS) since its inception 30 years back. The MBS is a key component of the Australian Medicare system. It lists Medicare subsidised services provided by health practitioners and private hospitals and sets out the ’Schedule fee’ for each service and the rate/s at which the benefit for that service is to be calculated. The purpose of this review is to ensure it reflects current best clinical practice and promotes the provision of health services that improve health outcomes. It is clinician led and is looking at opportunities for reform of the MBS over the short, medium and longer terms. As well as looking at specific MBS items, the Taskforce will also review the legislation and rules which underpin the MBS. (Full information see Department of Health website:
